Fig 1: GSEA of BTN2A2 in glioma. (A–I) The CTLA4, MHC, Th1-Th2, chemokine, and JAK-STAT signaling pathway, the processing and presentation of antigens, and apoptosis were determined using GSEA.
Fig 2: Correlation between BTN2A2 expression and CFs. (A) BTN2A2 expression in patients with glioma in TCGA cohort. (B, C) BTN2A2 expression in patients with glioma in GEO cohort. (D) BTN2A2 expression in normal human astrocytes cells (NHA) and glioma cells (A172, T98G, LN229, and SF295) was determined using qRT-PCR. (E–G) Correlation between BTN2A2 expression and CFs (grade, IDH status, 1p/19q codeletion, age, primary therapeutic outcome, and histological type). *P < 0.05, **P < 0.01, ***P < 0.001.
Supplier Page from Abcam for Anti-BTN2A2/BTF2 antibody [6C7D2]